A general method for making peptide therapeutics resistant to serine protease degradation: Application to dipeptidyl peptidase IV substrates

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8339-8351

  Heard, Kathryn R ^a   Wu, Wengen ^a   Li, Youhua ^a   Zhao, Peng ^a   Woznica, Iwona ^a   Lai, Jack H ^a   Beinborn, Martin ^b   Sanford, David G ^a   Dimare, Matthew T ^a   Chiluwal, Amrita K ^a   Peters, Diane E ^a   Whicher, Danielle ^a   Sudmeier, James L ^a   Bachovchin, William W ^a  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA LYTIC PROTEINASE; CHYMOTRYPSIN; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; PEPTIDE DERIVATIVE; SEPRASE; SERINE PROTEINASE; TRYPSIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME DEGRADATION; ENZYME SPECIFICITY; ENZYME STABILITY; FEMALE; GLUCOSE BLOOD LEVEL; IC 50; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN CLEAVAGE; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RECEPTOR BINDING;

ANIMALS; DIPEPTIDYL PEPTIDASE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MOLECULAR STRUCTURE; PEPTIDES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84887965583     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400423p     Document Type: Article

References (58)

1. McGregor, D. P. Discovering and improving novel peptide therapeutics Curr. Opin. Pharmacol. 2008, 8 (5) 616-619
2. Saladin, P. M.; Zhang, B. D.; Reichert, J. M. Current trends in the clinical development of peptide therapeutics IDrugs 2009, 12 (12) 779-784
3. Deacon, C. F.; Johnsen, A. H.; Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J. Clin. Endocrinol. Metab. 1995, 80 (3) 952-957
4. Deacon, C. F.; Nauck, M. A.; Meier, J.; Hucking, K.; Holst, J. J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide J. Clin. Endocrinol. Metab. 2000, 85 (10) 3575-3581
5. Mentlein, R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul. Pept. 1999, 85 (1) 9-24
6. Pospisilik, J. A.; Hinke, S. A.; Pederson, R. A.; Hoffmann, T.; Rosche, F.; Schlenzig, D.; Glund, K.; Heiser, U.; McIntosh, C. H.; Demuth, H. Metabolism of glucagon by dipeptidyl peptidase IV (CD26) Regul. Pept. 2001, 96 (3) 133-141
7. Schjoldager, B. T.; Baldissera, F. G.; Mortensen, P. E.; Holst, J. J.; Christiansen, J. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man Eur. J. Clin. Invest. 1988, 18 (5) 499-503
8. Grouzmann, E.; Fathi, M.; Gillet, M.; de Torrente, A.; Cavadas, C.; Brunner, H.; Buclin, T. Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma Clin. Chem. 2001, 47 (6) 1075-1082
9. Clerico, A.; Iervasi, G.; Mariani, G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans Horm. Metab. Res. 1999, 31 (9) 487-498
10. Bouras, M.; Huneau, J. F.; Luengo, C.; Erlanson-Albertsson, C.; Tome, D. Metabolism of enterostatin in rat intestine, brain membranes, and serum: differential involvement of proline-specific peptidases Peptides 1995, 16 (3) 399-405
11. Hojberg, P. V.; Vilsboll, T.; Rabol, R.; Knop, F. K.; Bache, M.; Krarup, T.; Holst, J. J.; Madsbad, S. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes Diabetologia 2009, 52 (2) 199-207
12. Nauck, M. A.; Kleine, N.; Orskov, C.; Holst, J. J.; Willms, B.; Creutzfeldt, W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 1993, 36 (8) 741-744
13. Toft-Nielsen, M. B.; Madsbad, S.; Holst, J. J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients Diabetes Care 1999, 22 (7) 1137-1143
14. Cohen, M. A.; Ellis, S. M.; Le Roux, C. W.; Batterham, R. L.; Park, A.; Patterson, M.; Frost, G. S.; Ghatei, M. A.; Bloom, S. R. Oxyntomodulin suppresses appetite and reduces food intake in humans J. Clin. Endocrinol. Metab. 2003, 88 (10) 4696-4701
15. Day, J. W.; Ottaway, N.; Patterson, J. T.; Gelfanov, V.; Smiley, D.; Gidda, J.; Findeisen, H.; Bruemmer, D.; Drucker, D. J.; Chaudhary, N.; Holland, J.; Hembree, J.; Abplanalp, W.; Grant, E.; Ruehl, J.; Wilson, H.; Kirchner, H.; Lockie, S. H.; Hofmann, S.; Woods, S. C.; Nogueiras, R.; Pfluger, P. T.; Perez-Tilve, D.; DiMarchi, R.; Tschop, M. H. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nature Chem. Biol. 2009, 5 (10) 749-757
16. Kerr, B. D.; Flatt, P. R.; Gault, V. A. (d -Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions Biochem. Pharmacol. 2010, 80 (11) 1727-1735
17. Meier, J. J.; Gallwitz, B.; Askenas, M.; Vollmer, K.; Deacon, C. F.; Holst, J. J.; Schmidt, W. E.; Nauck, M. A. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes Diabetologia 2005, 48 (9) 1872-1881
18. Meneilly, G. S.; Bryer-Ash, M.; Elahi, D. The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide Diabetes Care 1993, 16 (1) 110-114
19. Wynne, K.; Park, A. J.; Small, C. J.; Meeran, K.; Ghatei, M. A.; Frost, G. S.; Bloom, S. R. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial Int. J. Obes. 2006, 30 (12) 1729-1736
20. Wynne, K.; Park, A. J.; Small, C. J.; Patterson, M.; Ellis, S. M.; Murphy, K. G.; Wren, A. M.; Frost, G. S.; Meeran, K.; Ghatei, M. A.; Bloom, S. R. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial Diabetes 2005, 54 (8) 2390-2395
21. Erlanson-Albertsson, C.; York, D. Enterostatin-a peptide regulating fat intake Obes. Res. 1997, 5 (4) 360-372
22. Lin, L.; Park, M.; York, D. A. Enterostatin inhibition of dietary fat intake is modulated through the melanocortin system Peptides 2007, 28 (3) 643-649
23. Mei, J.; Erlanson-Albertsson, C. Effect of enterostatin given intravenously and intracerebroventricularly on high-fat feeding in rats Regul. Pept. 1992, 41 (3) 209-218
24. Redrobe, J. P.; Dumont, Y.; St-Pierre, J. A.; Quirion, R. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition Brain Res. 1999, 848 (1-2) 153-166
25. Thorsell, A.; Karlsson, R. M.; Heilig, M. NPY in alcoholism and psychiatric disorders EXS 2006, 95, 183-192
26. Thorsell, A.; Slawecki, C. J.; El Khoury, A.; Mathe, A. A.; Ehlers, C. L. The effects of social isolation on neuropeptide Y levels, exploratory and anxiety-related behaviors in rats Pharmacol., Biochem. Behav. 2006, 83 (1) 28-34
27. Cheng, J. W. Nesiritide: review of clinical pharmacology and role in heart failure management Heart Dis. 2002, 4 (3) 199-203
28. Grantham, J. A.; Borgeson, D. D.; Burnett, J. C., Jr. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure Am. J. Physiol. 1997, 272 (4 Pt 2) R1077-R1083
29. Sonnichsen, F. D.; Van Eyk, J. E.; Hodges, R. S.; Sykes, B. D. Effect of trifluoroethanol on protein secondary structure: an NMR and CD study using a synthetic actin peptide Biochemistry 1992, 31 (37) 8790-8798
30. Bjelke, J. R.; Kanstrup, A. B.; Rasmussen, H. B. Selectivity among dipeptidyl peptidases of the S9b family Cell. Mol. Biol. 2006, 52 (4) 3-7
31. Keane, F. M.; Nadvi, N. A.; Yao, T. W.; Gorrell, M. D. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha FEBS J. 2011, 278 (8) 1316-1332
32. Mentlein, R.; Roos, T. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells Peptides 1996, 17 (4) 709-720
33. Brandt, I.; Lambeir, A. M.; Ketelslegers, J. M.; Vanderheyden, M.; Scharpe, S.; De Meester, I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form Clin Chem 2006, 52 (1) 82-87
34. Mentlein, R.; Dahms, P.; Grandt, D.; Kruger, R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV Regul. Pept. 1993, 49 (2) 133-144
35. Mentlein, R.; Gallwitz, B.; Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 1993, 214 (3) 829-835
36. Green, B. D.; Gault, V. A.; Irwin, N.; Mooney, M. H.; Bailey, C. J.; Harriott, P.; Greer, B.; Flatt, P. R.; O'Harte, F. P. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1 Biol. Chem. 2003, 384 (12) 1543-1551
37. Green, B. D.; Mooney, M. H.; Gault, V. A.; Irwin, N.; Bailey, C. J.; Harriott, P.; Greer, B.; Flatt, P. R.; O'Harte, F. P. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39) Metabolism 2004, 53 (2) 252-259
38. Gault, V. A.; Hunter, K.; Irwin, N.; Green, B. D.; Greer, B.; Harriott, P.; O'Harte, F. P.; Flatt, P. R. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists Arch. Biochem. Biophys. 2007, 461 (2) 263-274
39. Druce, M. R.; Minnion, J. S.; Field, B. C.; Patel, S. R.; Shillito, J. C.; Tilby, M.; Beale, K. E.; Murphy, K. G.; Ghatei, M. A.; Bloom, S. R. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs Endocrinology 2009, 150 (4) 1712-1722
40. Santoprete, A.; Capito, E.; Carrington, P. E.; Pocai, A.; Finotto, M.; Langella, A.; Ingallinella, P.; Zytko, K.; Bufali, S.; Cianetti, S.; Veneziano, M.; Bonelli, F.; Zhu, L.; Monteagudo, E.; Marsh, D. J.; Sinharoy, R.; Bianchi, E.; Pessi, A. DPP-IV-resistant, long-acting oxyntomodulin derivatives J. Pept. Sci. 2011, 17 (4) 270-280
41. Al-Sabah, S.; Donnelly, D. The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists FEBS Lett. 2003, 553 (3) 342-346
42. Al-Sabah, S.; Donnelly, D. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors Br. J. Pharmacol. 2003, 140 (2) 339-346
43. Cabrele, C.; Beck-Sickinger, A. G. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family J. Pept. Sci. 2000, 6 (3) 97-122
44. Mimeault, M.; De Lean, A.; Lafleur, M.; Bonenfant, D.; Fournier, A. Evaluation of conformational and binding characteristics of various natriuretic peptides and related analogs Biochemistry 1995, 34 (3) 955-964
45. Xiao, Q.; Giguere, J.; Parisien, M.; Jeng, W.; St-Pierre, S. A.; Brubaker, P. L.; Wheeler, M. B. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo Biochemistry 2001, 40 (9) 2860-2869
46. Hinke, S. A.; Manhart, S.; Speck, M.; Pederson, R. A.; Demuth, H. U.; McIntosh, C. H. In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide Life Sci. 2004, 75 (15) 1857-1870
47. Gault, V. A.; O'Harte, F. P.; Harriott, P.; Flatt, P. R. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide Biochem. Biophys. Res. Commun. 2002, 290 (5) 1420-1426
48. Baldissera, F. G.; Holst, J. J.; Knuhtsen, S.; Hilsted, L.; Nielsen, O. V. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs Regul. Pept. 1988, 21 (1-2) 151-166
49. Gros, L.; Thorens, B.; Bataille, D.; Kervran, A. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line Endocrinology 1993, 133 (2) 631-638
50. Runge, S.; Gram, C.; Brauner-Osborne, H.; Madsen, K.; Knudsen, L. B.; Wulff, B. S. Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus J. Biol. Chem. 2003, 278 (30) 28005-28010
51. Beck-Sickinger, A. G.; Wieland, H. A.; Wittneben, H.; Willim, K. D.; Rudolf, K.; Jung, G. Complete l -alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations Eur. J. Biochem. 1994, 225 (3) 947-958
52. Grandt, D.; Schimiczek, M.; Rascher, W.; Feth, F.; Shively, J.; Lee, T. D.; Davis, M. T.; Reeve, J. R., Jr.; Michel, M. C. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors Regul. Pept. 1996, 67 (1) 33-37
53. Kuhn-Wache, K.; Bar, J. W.; Hoffmann, T.; Wolf, R.; Rahfeld, J. U.; Demuth, H. U. Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site Biol. Chem. 2011, 392 (3) 223-231
54. Yoshimoto, T.; Orawski, A. T.; Simmons, W. H. Substrate specificity of aminopeptidase P from Escherichia coli: comparison with membrane-bound forms from rat and bovine lung Arch. Biochem. Biophys. 1994, 311 (1) 28-34
55. Aertgeerts, K.; Levin, I.; Shi, L.; Snell, G. P.; Jennings, A.; Prasad, G. S.; Zhang, Y.; Kraus, M. L.; Salakian, S.; Sridhar, V.; Wijnands, R.; Tennant, M. G. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha J. Biol. Chem. 2005, 280 (20) 19441-19444
56. a determination of the Asp102 side chain in a serine protease J. Am. Chem. Soc. 2012, 134 (4) 2348-2354
57. Tibaduiza, E. C.; Chen, C.; Beinborn, M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain J. Biol. Chem. 2001, 276 (41) 37787-37793
58. Fortin, J. P.; Ci, L.; Schroeder, J.; Goldstein, C.; Montefusco, M. C.; Peter, I.; Reis, S. E.; Huggins, G. S.; Beinborn, M.; Kopin, A. S. The μ-Opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs Mol. Pharmacol. 2010, 78 (5) 837-845